MCID: PRM014
MIFTS: 30

Periampullary Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Periampullary Adenocarcinoma

MalaCards integrated aliases for Periampullary Adenocarcinoma:

Name: Periampullary Adenocarcinoma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:8110
NCIt 50 C27322
UMLS 73 C1335377

Summaries for Periampullary Adenocarcinoma

MalaCards based summary : Periampullary Adenocarcinoma is related to adenocarcinoma and neurofibromatosis, type i, and has symptoms including abdominal pain An important gene associated with Periampullary Adenocarcinoma is PIGR (Polymeric Immunoglobulin Receptor), and among its related pathways/superpathways are Pyrimidine metabolism and Signaling by PTK6. The drugs Pancrelipase and Thrombin have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and endothelial, and related phenotypes are digestive/alimentary and immune system

Related Diseases for Periampullary Adenocarcinoma

Diseases related to Periampullary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.9
2 neurofibromatosis, type i 10.1
3 pancreatic cancer 10.0
4 somatostatinoma 10.0
5 paraganglioma 10.0
6 bile duct cancer 10.0
7 pancreas adenocarcinoma 9.8 DCK SLC29A1

Graphical network of the top 20 diseases related to Periampullary Adenocarcinoma:



Diseases related to Periampullary Adenocarcinoma

Symptoms & Phenotypes for Periampullary Adenocarcinoma

UMLS symptoms related to Periampullary Adenocarcinoma:


abdominal pain

MGI Mouse Phenotypes related to Periampullary Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.26 CDKN1B ERBB3 PIGR SATB2
2 immune system MP:0005387 9.02 CDKN1B DCK ERBB3 PIGR SLC29A1

Drugs & Therapeutics for Periampullary Adenocarcinoma

Drugs for Periampullary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
2
Thrombin Approved, Investigational Phase 4
3 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
4 Hemostatics Phase 4
5 Coagulants Phase 4
6 Fibrin Tissue Adhesive Phase 4
7
Ethanol Approved Phase 3 64-17-5 702
8 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Infective Agents, Local Phase 3
10 Central Nervous System Depressants Phase 3
11
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
12
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
13
Fluorouracil Approved Phase 2 51-21-8 3385
14
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
15
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
16
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
17
leucovorin Approved Phase 2 58-05-9 6006 143
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19
Maleic acid Experimental Phase 2 110-16-7 444266
20
Cediranib Investigational Phase 2 288383-20-0 9933475
21
s 1 (combination) Phase 2
22 Antimetabolites, Antineoplastic Phase 2,Phase 1
23 Liver Extracts Phase 2,Phase 1
24 Antiviral Agents Phase 2,Phase 1
25 Antimetabolites Phase 2,Phase 1
26
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
27 Protein Kinase Inhibitors Phase 2,Phase 1
28 Immunosuppressive Agents Phase 2,Phase 1
29 Immunologic Factors Phase 2,Phase 1
30 Calcium, Dietary Phase 2
31 Vitamin B9 Phase 2
32 Vitamins Phase 2
33 Trace Elements Phase 2
34 Antidotes Phase 2
35 Protective Agents Phase 2
36 Folate Phase 2
37 Vitamin B Complex Phase 2
38 Micronutrients Phase 2
39
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
40
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
41
motexafin gadolinium Investigational Phase 1 156436-89-4 12047567
42 Histone Deacetylase Inhibitors Phase 1
43 Photosensitizing Agents Phase 1
44 Dermatologic Agents Phase 1
45 Orange Approved Not Applicable
46
Paclitaxel Approved, Vet_approved 33069-62-4 36314
47
Cefotaxime Approved Not Applicable 63527-52-6 456256 5742673
48
Cefoxitin Approved Not Applicable 35607-66-0 441199
49
Vitamin A Approved, Nutraceutical, Vet_approved Early Phase 1 11103-57-4, 68-26-8 445354
50 Retinol palmitate Early Phase 1

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
2 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
3 Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer Completed NCT00806611 Phase 3
4 Effect of Probiotics in Patients Undergoing Surgery for Periampullary Neoplasms Completed NCT01468779 Phase 3
5 SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer Unknown status NCT01811277 Phase 2 SOX sequential S-1
6 Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma Active, not recruiting NCT01781728 Phase 2
7 Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Terminated NCT00832637 Phase 2 Cisplatin;Erlotinib;Gemcitabine
8 Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Terminated NCT01229111 Phase 2 cediranib maleate;oxaliplatin;leucovorin calcium;fluorouracil
9 Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer Withdrawn NCT00487851 Phase 2
10 Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer Completed NCT00983268 Phase 1 capecitabine;vorinostat
11 Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery Completed NCT00003798 Phase 1 motexafin gadolinium
12 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
13 Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy Unknown status NCT01913275 Not Applicable
14 Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer Completed NCT02900950 Not Applicable
15 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276 Not Applicable
16 Fatigue and Pancreas and Bile Duct Cancer Study Completed NCT00902759 Early Phase 1
17 Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy Completed NCT00841607 Not Applicable
18 Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Completed NCT02081131 Not Applicable
19 Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage Completed NCT01789502 Not Applicable
20 Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer Completed NCT00409864 Not Applicable
21 Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer Recruiting NCT03724994 Gemcitabine
22 Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer Recruiting NCT02787512 Not Applicable
23 Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region Recruiting NCT02780648 Early Phase 1
24 Impact of Additional DJ (Duodenojejunostomy)-Pexy on Reduction in Delayed Gastric Emptying Following Pylorus-preserving Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial Recruiting NCT02635399 Not Applicable
25 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615 Not Applicable
26 Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient Recruiting NCT02958059 Not Applicable
27 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02757859 Not Applicable
28 EUS BD vs ERCP TP for Pancreatic Cancer Recruiting NCT03063554 Not Applicable
29 Margin Status After Pancreaticoduodenectomy for Cancer Active, not recruiting NCT03267966 Not Applicable
30 Failure to Adjuvant Therapy After Pancreatic Resection for Malignant Tumors Not yet recruiting NCT03788382
31 Comparing Three Dimension Laparoscopic Versus Open Pancreaticoduodenectomy Not yet recruiting NCT03138213 Not Applicable

Search NIH Clinical Center for Periampullary Adenocarcinoma

Genetic Tests for Periampullary Adenocarcinoma

Anatomical Context for Periampullary Adenocarcinoma

MalaCards organs/tissues related to Periampullary Adenocarcinoma:

41
Liver, Lymph Node, Endothelial, Pancreas

Publications for Periampullary Adenocarcinoma

Articles related to Periampullary Adenocarcinoma:

(show top 50) (show all 60)
# Title Authors Year
1
Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. ( 29540182 )
2018
2
Surgical management of periampullary adenocarcinoma: defining an optimal prognostic lymph node stratification schema. ( 29760806 )
2018
3
Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy. ( 29580215 )
2018
4
Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma. ( 30216219 )
2018
5
Immunohistochemical expression of CDX2, CK7, HER2 and HER4 in periampullary adenocarcinoma : implications for clinicopathology and patient outcomes. ( 29364095 )
2017
6
The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype. ( 28673320 )
2017
7
Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. ( 28518410 )
2017
8
The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. ( 27275582 )
2016
9
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma. ( 27488532 )
2016
10
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. ( 27070783 )
2016
11
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma. ( 26590090 )
2016
12
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. ( 26361410 )
2015
13
Management of periampullary adenocarcinoma by pancreaticoduodenectomy at a regional teaching hospital. ( 26261725 )
2015
14
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. ( 26362587 )
2015
15
A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma. ( 25667135 )
2015
16
Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. ( 26028992 )
2015
17
Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma. ( 26515733 )
2015
18
Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. ( 25397670 )
2014
19
A case of periampullary adenocarcinoma in neurofibromatosis type 1. ( 25436139 )
2014
20
Mixed periampullary adenocarcinoma and somatostatinoma with small bowel gastrointestinal stromal tumour in neurofibromatosis type 1. ( 25435578 )
2014
21
Use of a standardized diagnostic approach improves the prognostic information of histopathologic factors in pancreatic and periampullary adenocarcinoma. ( 24731283 )
2014
22
Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. ( 25323550 )
2014
23
Large retroperitoneal paraganglioma concurrent with periampullary adenocarcinoma. ( 24523807 )
2013
24
Ampullary and periampullary adenocarcinoma: new challenges in management of recurrence. ( 23474562 )
2013
25
FAP related periampullary adenocarcinoma. ( 23792481 )
2013
26
Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. ( 23601033 )
2013
27
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. ( 22551547 )
2012
28
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. ( 22782416 )
2012
29
Adjuvant chemotherapy for resected periampullary adenocarcinoma. ( 23149995 )
2012
30
Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. ( 18547417 )
2008
31
Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization. ( 18580212 )
2008
32
Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. ( 17336242 )
2007
33
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. ( 17084719 )
2006
34
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma. ( 15978737 )
2005
35
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. ( 16332474 )
2005
36
Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma. ( 15011922 )
2004
37
Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. ( 15531230 )
2004
38
Cyclin D1 and bax influence the prognosis after pancreatoduodenectomy for periampullary adenocarcinoma. ( 15532837 )
2004
39
Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. ( 12559179 )
2003
40
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. ( 12192322 )
2002
41
Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. ( 11677994 )
2001
42
Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. ( 11520088 )
2001
43
The Johns Hopkins experience with pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. ( 10939866 )
2000
44
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( 11072167 )
2000
45
Prospective study of gastric outlet obstruction in unresectable periampullary adenocarcinoma. ( 10594205 )
2000
46
Implications of histological grade of tumour for the prognosis of radically resected periampullary adenocarcinoma. ( 10533763 )
1999
47
Periampullary adenocarcinoma: analysis of 5-year survivors. ( 10561100 )
1999
48
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. ( 10421536 )
1999
49
Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. ( 10359359 )
1999
50
Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. ( 10235519 )
1999

Variations for Periampullary Adenocarcinoma

Expression for Periampullary Adenocarcinoma

Search GEO for disease gene expression data for Periampullary Adenocarcinoma.

GO Terms for Periampullary Adenocarcinoma

Biological processes related to Periampullary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleobase-containing compound metabolic process GO:0006139 8.62 DCK SLC29A1

Sources for Periampullary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....